Navigation Links
DaVita 3rd Quarter 2008 Results
Date:11/2/2008

tal expenditures:

Development and

relocations $51.6 $60.2 $48.5 $158.0

Routine

maintenance/IT

other $27.2 $20.2 $22.6 $65.9

Acquisition

expenditures $31.5 $60.9 $75.5 $101.2

Accounts Receivable

Net receivables $1,057 $1,047 $976

DSO 70 70 70

Debt/Capital Structure

Total debt(2) $3,704 $3,705 $3,701

Net debt, net of

cash(2) $3,316 $3,378 $3,309

Leverage ratio

(see Note 1) 2.98x 3.07x 3.10x

Overall effective

weighted average

interest rate

during the quarter 5.66% 5.75% 6.48%

Overall effective

weighted average

interest rate end

of the quarter 6.09% 5.68% 6.43%

Effective weighted

average interest

rate on the Senior

Secured Credit

Facilities end of

the quarter 5.39% 4.59% 6.00%

Economically fixed

interest rates as

a percentage of

our total debt 70% 69% 77%

Share repurchases $- $137.2 $- $169.7

Clinical (quarterly averages)

Dialysis adequacy

-% of patients

with Kt/V > 1.2 94% 95% 94%

Patients with

Hb>=10 <=13 87% 86% 80%

Patients with

arteriovenous

fistulas placed 61% 60% 57%

(1) These are non-GAAP financial measures. For a reconciliation of these

non-GAAP financial measures to their most comparable measure

calculated and presented in accordance with GA
'/>"/>

SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Spokesman at the United Nations Joins DaVita
2. Tour DaVita Rides to Improve Kidney Disease Education
3. DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France
4. DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards
5. DaVita Renal Dietitians Conduct First-Ever EYE on CKD Workshop
6. DaVita Board of Directors Increases Share Repurchase Authorization
7. DaVita 4th Quarter 2007 Results
8. DaVita Announces Chief Financial Officer
9. Nations Leading Dialysis Provider - DaVita - Partners with eDiets(R) to Launch One-of-a-Kind Diet Helper Online Nutrition and Meal Planning Tool for Late-Stage Kidney Disease Patients and Caregivers
10. DaVita and Phoenix-Based Southwest Kidney Institute Form Broad Partnership
11. DaVita Inc. to Present at JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... mesothelioma develops, may extend and improve the lives of patients, according to a ... Click here to read the full article. , The authors of ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik ... zero standard shipping costs. , “Before, a threshold of $49.00 was required to qualify ... and items qualify for free standard shipping for customers regardless of the item’s selling ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... the Ganesh Shanker Vidyarthi Memorial (GSVM) Medical College have ... // in bringing medical knowledge and technology that would ... ,The two institutes have signed a memorandum ... increased collaboration on several fronts. ,The heads ...
... Association (AMA) says that the federal budget has poorly ... for not addressing problems like obesity //and indigenous health. ... develop world-first medical technologies to fight cancer and heart ... for the National Health and Medical Research Council by ...
... Japanese Encephalitis immunisation which was initially scheduled to take ... 15. //The Uttar Pradesh government is responsible for the ... dates. Japanese Encephalitis is the main reason for the ... Statistics show that in UP alone about 600-700 children ...
... of fungal infection in Bausch and Lomb lens wearers are ... association arrived at is that nearly 50% of those who ... solution, manufactured by Bausch and Lomb. ,Bausch & ... solution, feels that the cause of Fusarium keratitis infection is ...
... study, drinking tap water increases the risk of bladder cancer. ... if one drink too much of it may be a ... published in the April 15 issue of International Journal of ... based drinks each day increased the risk of bladder cancer ...
... Research (ICAR) has identified Indira Kankoda I (RMF 37), ... Chhattisgarh, Uttar Pradesh, Jharkhand, Orissa and Maharashtra. ... will be the first spine gourd variety identified for ... vegetable crop locally known as Meetha Karela, Khekhsa, Padora ...
Cached Medicine News:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... -- According to a new market research report "Medical ... Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End ... the Medical Lifting Sling Market is poised to reach USD 706.0 ... CAGR of 11.4 % from 2015 to 2020. ... T ables and 65 F ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2011 Reportlinker.com announces that a new market ... Gastric Cancer - Global Drug Forecasts ... 2011 http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html ... Treatment Analysis to 2020 – Volume I 2011 ...
... April 12, 2011 Reportlinker.com announces that a new ... Bladder Cancer - Global Drug Forecasts and ... http://www.reportlinker.com/p0479812/Bladder-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020---Volume-1-2011.html Bladder Cancer ... - Volume 1 2011 Summary ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 2Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 3Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 4Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 5Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 6Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 7Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 8Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 9Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 10Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 12Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 13Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 14Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 15Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 16Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 17Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 18Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 19Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 20Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 21Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 22Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 2Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 3Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 4Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 5Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 6Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 7Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 8Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 9Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 10Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 11Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 12Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 13Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 14Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 15
... Lyphochek Fertility Control ... monitor the clinically significant ... most frequently assayed during ... Elevated hCG and hCG-Beta ...
Liquichek Spinal Fluid Control is a liquid, bilevel product designed to monitor the performance of automated and manual procedures for the analysis of proteins and other critical analytes assayed in ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
Medicine Products: